Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07228221 · ClinicalTrials.gov registry record · Phase 4
Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma
A Phase 4 study of Open Angle Glaucoma and Pigmentary Glaucoma, sponsored by Jonathon Myers.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07228221 is a Phase 4 study of Open Angle Glaucoma and Pigmentary Glaucoma that is actively recruiting participants, run by Jonathon Myers. The registered enrollment target is 20 participants, below the 334-participant average among 28 other Open Angle Glaucoma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07228221, a Phase 4 study of Open Angle Glaucoma and Pigmentary Glaucoma, is actively recruiting participants, sponsored by Jonathon Myers.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The Investigators will investigate the efficacy of combining the standalone iStent infinite and iDose that are minimally invasive surgical and drug depot options are a safe and effective alternative to filtering surgery for intraocuar pressure reduction in patients with medically uncontrolled open angle glaucoma.
Conditions Studied
Interventions
- DEVICE iStent infinite trabecular micro-bypass system model iS3
- DRUG iDose TR (Travoprost intracameral Implant) 75mcg
Study Locations (1)
Pennsylvania
- Wills Eye Hosital Glaucoma Dept. - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-01-05 |
| Est. Completion | 2031-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07228221
The ClinicalTrials.gov registry entry for NCT07228221 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 334-participant average among 28 other Open Angle Glaucoma trials with a reported enrollment target (94% lower). The listed sponsor is Jonathon Myers, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Open Angle Glaucoma appearing as the primary indexed condition, and to 2 interventions - of which iStent infinite trabecular micro-bypass system model iS3 is the first listed.
NCT07228221 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07228221 about?
NCT07228221 is a clinical study titled "Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma". The Investigators will investigate the efficacy of combining the standalone iStent infinite and iDose that are minimally invasive surgical and drug depot options are a safe and effective alternative to filtering surgery for intraocuar pressure reduction in patients with medically uncontrolled open a...
What is the current status of trial NCT07228221?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2026-01-05. Estimated completion is 2031-12-31.
What conditions does trial NCT07228221 study?
This clinical trial studies the following conditions: Open Angle Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma.
What interventions are being tested in trial NCT07228221?
The interventions under investigation include: iStent infinite trabecular micro-bypass system model iS3 (DEVICE), iDose TR (Travoprost intracameral Implant) 75mcg (DRUG).
Who is sponsoring clinical trial NCT07228221?
This trial is sponsored by Jonathon Myers, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07228221 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Open Angle Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
RECRUITING · Phase 4
-
Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost
RECRUITING · Phase 4
-
Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
RECRUITING · Phase 4
-
Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy
RECRUITING · NA
-
A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
RECRUITING · Phase 1
-
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.